NEW YORK (GenomeWeb News) - The National Institutes of Health is making a prostate cancer-related genotyping technology available for either exclusive or non-exclusive licensing.
The National Cancer Institute’s Medical Oncology Branch is seeking interested research collaborators to develop, evaluate, or commercialize the use of this technology, which is used to predict survival prognoses for prostate cancer patients.
The NCI’s genotyping technology identifies two polymorphic genetic markers in the SLCO 1B3 gene that can be measured in DNA from a blood sample.
The inventors have provided a correlation between clinical outcome of SLCO 1B3 genotype with median survival of androgen-independent prostate cancer. They also have shown that the genotype can help predict testosterone uptake, which can be helpful knowledge in making clinical decisions.
Additional information about the technology is available here.